

Special Issue

Stroke Genomics and Exit Strategies

Message from the Guest Editors

The inexorable shift towards personalized medicine, driven by the integration of genomic insights, is shaping the medical landscape. Notably, recent expansive genomic endeavors have unearthed numerous loci intricately linked to strokes, giving rise to the development of polygenic risk models. Whereas genomic medicine has already found its footing within oncology, driving treatment decisions via genomic analysis, its integration into the realm of stroke management remains an uncharted territory despite these remarkable advancements. Hence, the theme of social implementation emerges as a pivotal pursuit within stroke genomics. This Special Issue stands as a beacon for publishing cutting-edge research articles and reviews centered explicitly on stroke genomics. We extend a warm invitation to authors to submit their work, particularly those that illuminate exit strategies essential for the integration of genomic medicine in stroke care.

Guest Editors

Dr. Hiroyuki Ishiyama

Department of Neurology, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan

Dr. Tomotaka Tanaka

Department of Neurology, National Cerebral and Cardiovascular Center, Osaka 564-8565, Japan

Deadline for manuscript submissions

closed (15 October 2024)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/182278

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))